We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > EC5026

News List

EicOsis Successfully Completes Phase 1a Clinical Trial of EC5026 americanpharmaceuticalreview
December 01, 2020
EicOsis Human Health announced the successful completion of a Phase 1a single-ascending dose clinical trial of EC5026, their oral drug candidate for the treatment of pain.
EicOsis EC5026 Granted Fast Track Designation by FDA for Neuropathic Pain americanpharmaceuticalreview
April 10, 2020
EicOsis announced the U.S. Food & Drug Administration (FDA) has granted Fast Track designation to its lead drug candidate, EC5026, for the treatment of neuropathic pain.
EicOsis Announces First Subject Dosed in Pain Management Trial americanpharmaceuticalreview
December 16, 2019
EicOsis announced initiation of dosing for the first human subject in a Phase 1 trial of EC5026, the company's lead product candidate for pain management.